Comparison of serological assays used across the globe
CITF-funded scientists from Canadian Blood Services and Héma-Québec participated in an international study which looked to compare the different serological assays used across 27 countries to estimate seroprevalence.
Review on transmission characteristics of SARS-CoV-2 VOCs
A rapid scoping review highlighting the transmission characteristics of SARS-CoV-2 variants of concern (VOCs) was prepared by the Nova Scotia COVID-END Evidence Synthesis Group on behalf of the SPOR Evidence Alliance, which included CITF-funded investigator Dr. Lisa Barrett.
Players from the first line of defence against SARS-CoV-2 may dictate disease outcome
CITF Leadership Group member Dr. Allison McGeer and CITF-funded researcher Dr. Mario Ostrowski collaborated on a recent publication in iScience where they attempted to examine the early immune responses to SARS-CoV-2 infection.
Why COVID-19 vaccine efficacy matters for older people
Data on vaccine effectiveness among seniors is lacking since many vaccine trials do not include individuals over the age of 65.
Two studies from Ontario highlight the importance of sociodemographic factors and COVID-19 risk
As the COVID-19 pandemic moves into its third wave, it is apparent that socioeconomic determinants of health play a role in determining risk of infection.
A single dose of mRNA vaccine may trigger variant-resilient immune responses
Emerging SARS-CoV-2 variants are a significant source of concern, especially the most resistant ones, such as the one originally identified in South Africa (B.1.351).
Guidance for COVID-19 vaccine research in pregnant women
Studies exploring COVID-19 vaccination among pregnant women are likely to face unique methodological challenges.
NACI provides rationale for extending interval between COVID-19 vaccine doses
SARS-CoV-2 has caused worldwide disruption, morbidity and mortality. Although several vaccines have been approved by regulatory bodies, many countries have been faced with the issue of vaccine shortages.
Rapid point-of-care tests to detect SARS-CoV-2 antibodies are promising, but field results are not ideal
CITF Leadership Group member Dr. Mel Krajden and Muhammad Morshed who receives support from the CITF for another project, along with their team at the British Columbia Centre for Disease Control Public Health Laboratory, recently evaluated the sensitivity of rapid tests to detect antibodies to SARS-CoV-2 in blood samples under different testing settings.